OncoMatch/Clinical Trials/NCT06395844
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
Is NCT06395844 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies METR-NK cell(Metabolic Remodeling Nature Killer Cells) for ovarian cancer.
Treatment: METR-NK cell(Metabolic Remodeling Nature Killer Cells) — The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO IIIC, FIGO IV (FIGO)
Grade: high-grade
advanced (FIGO IIIC/IV stage) high-grade serous ovarian cancer, high-grade endometrioid carcinoma, primary peritoneal carcinoma, and/or fallopian tube carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cell immunotherapy
Lab requirements
Blood counts
hemoglobin ≥90g/l, white blood cell count ≥3×10^9/l, absolute neutrophil count (anc) ≥1.5×10^9/l, platelets ≥90×10^9/l
Kidney function
serum creatinine <1.5 mg/dl, glomerular filtration rate (gfr) ≥50 ml/min (based on the fairview laboratories formula at screening)
Liver function
ast, alt, and alkaline phosphatase <3 times the upper limit of normal for the institution, total bilirubin <1.5 times the upper limit of normal for the institution
Cardiac function
left ventricular ejection fraction (lvef) ≥40% by echocardiography, muga, or cardiac mri; no evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, or acute ischemia or active conduction system abnormalities on electrocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify